Content Type: Commentary & Opinion

Same Song, Different Audience: Pharmaceutical Promotion Targeting Non-Physician Health Care Providers

March 16, 2026

Updating the Bayh-Dole Act: March-In Rights and Transparency

March 16, 2026

Pharmaceutical Advertising in Medical Journals

March 16, 2026

Prescription-Drug Coupons—No Such Thing as a Free Lunch

March 16, 2026

Challenges and Opportunities for Biomarker Validation

March 16, 2026

Direct-To-Consumer Generic Drugs: A Maverick Approach or Another Exposure of Market Failures?

March 16, 2026

Promoting Therapeutic Innovation: What Do We Do About Drug-Device Combinations?

March 16, 2026

Balancing Benefits and Harms: Privacy Protection Policies

March 16, 2026

Accelerated Approval and Expensive Drugs—A Challenging Combination

March 16, 2026

Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry

March 16, 2026

Real-World Evidence And Regulatory Drug Approval

March 16, 2026

Who Is Now Responsible for Discovering and Warning About Adverse Effects of Generic Drugs?

March 16, 2026